# Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs.

> PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42022682-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42022682-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42022682-teriparatide-v1.json
- Content SHA-256: `945afb4e35f8838ae91b1169aac1f44ee362cce3e5157e45c094db4f51549948`

## Claims and source pins

### Headline

Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

### Summary

PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

### Paragraph 1

PubMed lists PMID 42022682 in Health science reports as Journal Article, Review, with publication-date metadata of 2026-03-13 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`](#source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac))

## Sources

<a id="source-pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac"></a>
- **Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs. · retained source version 1:2026-08-13:current:7d54bf4840ac5fd2a4e97b9f12fb252d111c2c3b2586ecae8ca745977c37c4d4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42022682/) (`pubmed-observation-pmid-42022682-2026-08-13-7d54bf4840ac`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Comparing Teriparatide and Bisphosphonates for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of RCTs." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42022682-teriparatide-v1.json SHA-256: 945afb4e35f8838ae91b1169aac1f44ee362cce3e5157e45c094db4f51549948.